Optic Neuritis Clinical Trial
— TONEOfficial title:
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
Verified date | November 2019 |
Source | University Eye Hospital, Freiburg |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial aims at preventing visual dysfunction and optic nerve degeneration associated with autoimmune optic neuritis by systemic i.v. administration of 33.000 IU erythropoietin over 3 days. The primary objective is to determine the efficacy of erythropoietin compared to placebo given as add-on to methylprednisolone as assessed by measurements of retinal nerve fibre layer thickness and low contrast visual acuity 6 months after acute optic neuritis.
Status | Completed |
Enrollment | 108 |
Est. completion date | November 26, 2019 |
Est. primary completion date | June 20, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Patients eligible for inclusion in this trial must meet all of the following criteria: 1. Written informed consent obtained according to international guidelines and local laws 2. Male and female patients aged = 18 to = 50 years 3. Patients with ON 4. First symptoms of ON = 10 days prior to the first administration of investigational product 5. High contrast visual acuity (HCVA) of = 0.5 (decimal system) 6. Adequate OCT measurements available Patients eligible for this trial must not meet any of the following criteria: 1. Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial 2. Simultaneous participation in another interventional trial which could interfere with this trial and/or participation in a clinical trial within the last 3 months before enrolment in this trial 3. Refractive anomalies: Hyperopia > 5 dpt, myopia < -7 dpt, astigmatism > 3 dpt 4. Media opacity 5. Severe papillitis 6. Previous ON 7. Any other optic nerve and retinal disease 8. Pre-existing MS or any other neurological disease 9. Congenital diseases: - thrombophilia - phenylketonuria 10. Acquired diseases: - autoimmune diseases, - cardiovascular diseases, - diabetes mellitus, - uncontrolled hypertension (with blood pressure > 140 / 90 mm Hg (cf. chapter 7.7.5)), - any malignancy, - epilepsy, - known tuberculosis with ongoing or unknown activity, - acute gastrointestinal ulceration within the last 3 months prior to randomisation, - acute viral, bacterial or fungal infection, - known infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus, - history of colitis ulcerosa, diverticulitis, or acute enteroanastomosis, - known osteoporosis, - history of thromboembolic events, - elevated haemoglobin level (>17 g/dl in men or >15 g/dl in women) - polycythaemia - any other significant illness potentially interfering with any trial assessment or trial treatment 11. Performing semi-professional or professional sporting activities or physical training 12. Pre-treatment with corticosteroids in the last 30 days prior to the onset of optic neuritis 13. Pre-treatment with EPO 14. Known or persistent abuse of medication, drugs or alcohol 15. Active immunization within 2 weeks prior to randomisation 16. Significant surgery within 4 weeks prior to randomisation 17. Blood donation or bloodletting within 4 weeks prior to screening 18. Pre-treatment with immunosuppressive or immunomodulatory agents 19. Persons who are in a relationship of dependence/employment with the sponsor or the investigator This section concerns only female patients who are able to have a child: 20. Current or planned pregnancy; nursing period within 3 months from investigational product administration 21. Unwillingness to use one of the following safe combination methods of contraception within 3 months from investigational product administration to achieve a PEARL index of <1: female condom, diaphragm or coil, each used in combination with a spermicide; hormonal intra-uterine device or hormonal contraception in combination with a mechanical method of contraception |
Country | Name | City | State |
---|---|---|---|
Germany | Duesseldorf University Hospital | Duesseldorf | Nordrhein-Westfalen |
Germany | University Hospital Erlangen | Erlangen | Bayern |
Germany | Medical Center - University of Freiburg, Eye Hospital | Freiburg | Baden-Wuerttemberg |
Germany | University Medical Center Göttingen | Göttingen | Niedersachsen |
Germany | University Medical Center Hamburg-Eppendorf | Hamburg | |
Germany | Hannover Medical School | Hannover | Niedersachsen |
Germany | Heidelberg University Hospital, Department of Neurooncology | Heidelberg | Baden-Wuerttemberg |
Germany | University Medical Center of the Johannes Gutenberg University Mainz | Mainz | Rheinland-Pfalz |
Germany | University Hospital Klinikum rechts der Isar, Munich | Munich | Bayern |
Germany | University Hospital of Munich | Munich | Bayern |
Germany | Tuebingen University Hospital | Tuebingen | Baden-Wuerttemberg |
Lead Sponsor | Collaborator |
---|---|
University Eye Hospital, Freiburg | German Federal Ministry of Education and Research |
Germany,
Diem R, Molnar F, Beisse F, Gross N, Drüschler K, Heinrich SP, Joachimsen L, Rauer S, Pielen A, Sühs KW, Linker RA, Huchzermeyer C, Albrecht P, Hassenstein A, Aktas O, Guthoff T, Tonagel F, Kernstock C, Hartmann K, Kümpfel T, Hein K, van Oterendorp C, Grotejohann B, Ihorst G, Maurer J, Müller M, Volkmann M, Wildemann B, Platten M, Wick W, Heesen C, Schiefer U, Wolf S, Lagrèze WA. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. BMJ Open. 2016 Mar 1;6(3):e010956. doi: 10.1136/bmjopen-2015-010956. — View Citation
Sühs KW, Hein K, Sättler MB, Görlitz A, Ciupka C, Scholz K, Käsmann-Kellner B, Papanagiotou P, Schäffler N, Restemeyer C, Bittersohl D, Hassenstein A, Seitz B, Reith W, Fassbender K, Hilgers R, Heesen C, Bähr M, Diem R. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012 Aug;72(2):199-210. doi: 10.1002/ana.23573. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Global retinal nerve fibre layer thickness (RNFLT-G) | Determination of the efficacy of erythropoietin compared to placebo given as add-on to methylprednisolone (standard of care) as assessed by measurement of global retinal nerve fibre layer thickness (RNFLT-G) in the affected eye 6 months after randomisation. | 6 months | |
Primary | Low contrast visual acuity (LCVA) | Determination of the efficacy of erythropoietin compared to placebo given as add-on to methylprednisolone (standard of care) as assessed by measurement of low contrast visual acuity (LCVA) in the affected eye 6 months after randomisation. | 6 months | |
Secondary | Absolute values of the global retinal nerve fibre layer thickness | 6 months | ||
Secondary | Retinal nerve fibre layer thickness in the papillomacular bundle | 6 months | ||
Secondary | Retinal nerve fibre layer thickness in the temporal quadrant | 6 months | ||
Secondary | Total macular volume | 6 months | ||
Secondary | Visual acuity | 6 months | ||
Secondary | Contrast sensitivity | 6 months | ||
Secondary | Mean visual field defect | 6 months | ||
Secondary | Latency [ms] and amplitude [µV] of visual evoked potentials (VEP) | 6 months | ||
Secondary | Expanded Disability Status Scale (EDSS) score | 6 months | ||
Secondary | Quality of life | Determined by NEI-VFQ-25 | 6 months | |
Secondary | Safety | Assessment of AEs / SAEs | Screening until end of study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Unknown status |
NCT00261326 -
Simvastatin Treatment of Patients With Acute Optic Neuritis
|
Phase 3 | |
Active, not recruiting |
NCT03963310 -
Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
|
||
Recruiting |
NCT03586557 -
Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis
|
N/A | |
Recruiting |
NCT05487989 -
VIsual Pathways Model in Neuro-inflammatory Disorders
|
||
Terminated |
NCT04131764 -
Diagnosis of ON With or Without MS or NMOSD
|
||
Not yet recruiting |
NCT06453694 -
Efgartigimod for the Treatment of Acute Optic Neuritis
|
Phase 2 | |
Recruiting |
NCT03302585 -
High-Dose Vitamin D Induction in Optic Neuritis
|
Phase 2 | |
Recruiting |
NCT02886377 -
The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset
|
N/A | |
Completed |
NCT01987167 -
Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
|
Early Phase 1 | |
Completed |
NCT01451593 -
Neuroprotection With Phenytoin in Optic Neuritis
|
Phase 2 | |
Completed |
NCT03630497 -
BN201 SAD MAD Study in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01337986 -
Ampyra for Optic Neuritis in Multiple Sclerosis
|
Phase 2/Phase 3 | |
Completed |
NCT01274702 -
Visual Reconstitution Therapy After Optic Neuritis
|
Phase 2 | |
Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
Withdrawn |
NCT00037115 -
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
|
Phase 4 | |
Not yet recruiting |
NCT06389968 -
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT04257734 -
Epidemiologic and Clinical Characteristics of Optic Neuritis in China
|
||
Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
Completed |
NCT02939937 -
Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
|
Phase 2 | |
Recruiting |
NCT04148781 -
Fampridine-SR and Optic Neuritis Recovery
|
Early Phase 1 |